AI has the potential to transform clinical research. In this webinar, Charles Fisher, Founder and CEO of Unlearn.AI, will provide an overview of artificial intelligence, and its innovative uses in clinical research. He will define machine learning (ML) and introduce how proprietary ML models can generate Digital Twins, or virtual patients, in external control arms of clinical trials. Incorporating Digital Twins into clinical trials can increase statistical power, accelerate trial timelines, and enable patient level insights, elevating clinical decision making and guiding future trial design. In this webinar, you will learn about:
Clinical trials are critical for developing new treatments, but face chronic challenges, such as optimal trial design, enrollment, costs, timeline delays, and high failure rates. The gold standard of trial design is randomization, but it is not always ethical or feasible to set up a trial where the control group receives a standard of care or a placebo. Leveraging historical data sets and novel machine learning methods, Digital Twins, or statistically indistinguishable virtual placebo patients, can be generated to match actual patients in clinical studies. Adding external control arms populated with Digital Twins, called Intelligent Control Arms, can streamline clinical trials, increase power, and decrease enrollment, without adding regulatory risk. The FDA has expressed support for innovation in trial design and alternative forms of evidence - Digital Twins are the next frontier for modern trials.
In this 3 part webinar series, you will learn about:
Who should attend?
Charles is a scientist with interests at the intersection of physics, machine learning, and computational biology. Previously, Charles worked as a machine learning engineer at Leap Motion and a computational biologist at Pfizer. He was a Philippe Meyer Fellow in theoretical physics at École Normale Supérieure in Paris, France, and a postdoctoral scientist in biophysics at Boston University. Charles holds a Ph.D. in biophysics from Harvard University and a B.S. in biophysics from the University of Michigan.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.